Taxanes

What it is

Taxanes are chemotherapy drugs that block cell division by stabilising microtubules; the main agents are paclitaxel, docetaxel, and cabazitaxel. This drug class includes 3 commonly used agents in modern oncology, with paclitaxel and docetaxel used widely for breast, ovarian, lung, and head and neck cancers, and cabazitaxel used mainly in prostate cancer after prior treatment.

Taxanes are a core part of treatment for many solid tumours. They may be given alone or with other anticancer drugs, targeted therapy, immunotherapy, surgery, or radiation depending on the cancer type and stage. In India, taxanes are routinely used in tertiary cancer centres and day-care chemotherapy units, including as part of standard regimens for breast and ovarian cancer.

Common taxanes include:

Drug	Common use areas	Notable point
Paclitaxel	Breast, ovarian, lung, head and neck, Kaposi sarcoma	Often causes peripheral neuropathy and requires premedication
Docetaxel	Breast, prostate, gastric, head and neck, lung	Neutropenia and fluid retention are important toxicities
Cabazitaxel	Prostate cancer	Often used after docetaxel in advanced disease
Albumin-bound paclitaxel (nab-paclitaxel)	Breast, lung, pancreatic cancer	Solvent-free formulation; hypersensitivity risk differs from standard paclitaxel

How it works

Taxanes act on the cell skeleton, specifically microtubules, which are needed for cells to separate their chromosomes during mitosis. Instead of allowing normal microtubule assembly and disassembly, taxanes stabilise these structures too strongly. That prevents proper spindle function, arrests cells in mitosis, and can trigger cancer cell death.

Because cancer cells divide more quickly than many normal cells, they are often more affected by taxanes. But normal fast-growing tissues are also exposed, which explains many side effects. Bone marrow suppression can lower white blood cells, hair follicles can be damaged causing hair loss, and nerves can be affected causing numbness or tingling.

Different taxanes are not identical. Paclitaxel and docetaxel have overlapping mechanisms but differ in formulation, schedule, metabolism, and toxicity profile. Nab-paclitaxel uses albumin-bound particles rather than the solvent used in conventional paclitaxel, which changes infusion practice and some adverse-effect patterns.

Evidence and uses

Taxanes are established anticancer medicines, not experimental drugs. Evidence from randomised trials and systematic reviews supports their use in several cancers, especially breast cancer. Cochrane reviews have found that adding a taxane to standard chemotherapy for early breast cancer improves survival and reduces recurrence risk, although it also increases some side effects such as febrile neutropenia and neuropathy.

They are commonly used in:

1. Breast cancer: in neoadjuvant, adjuvant, and metastatic settings.
2. Ovarian cancer: often with platinum chemotherapy.
3. Non-small cell lung cancer: in selected regimens.
4. Prostate cancer: docetaxel and later-line cabazitaxel in advanced disease.
5. Head and neck cancers: as part of combination chemotherapy in some settings.
6. Gastric and pancreatic cancers: in selected protocols, including nab-paclitaxel for pancreatic cancer.

Taxanes are usually given by intravenous infusion in cycles, often every 1, 2, or 3 weeks depending on the regimen. The exact schedule matters because weekly and 3-weekly dosing can differ in both effectiveness and side effects. For example, weekly paclitaxel is often used when clinicians want a different balance between response and toxicity.

Choice of taxane depends on the cancer, prior treatment, liver function, expected side effects, cost, and availability. In India, generic paclitaxel and docetaxel are widely available, while nab-paclitaxel and cabazitaxel may be more expensive or used more selectively.

Safety and interactions

Taxanes can cause serious side effects, so they should be given under oncology supervision. Important toxicities include:

Side effect	Why it matters
Neutropenia	Can lead to severe infection or febrile neutropenia
Peripheral neuropathy	Numbness, tingling, burning pain, weakness; may persist after treatment
Hypersensitivity reactions	Can occur during infusion, especially with solvent-based formulations
Hair loss	Very common with paclitaxel and docetaxel
Nail and skin changes	Discoloration, brittleness, tenderness
Mucositis or diarrhoea	Can affect eating and hydration
Fluid retention	More associated with docetaxel
Liver-related concerns	Dose changes may be needed if liver tests are abnormal

Premedication is often used to reduce infusion reactions, especially with standard paclitaxel and docetaxel. Blood counts and liver function tests are usually checked before treatment cycles.

Drug interactions matter. Taxanes are metabolised through liver enzyme pathways, especially CYP3A4 and related systems, so some antifungals, antibiotics, seizure medicines, HIV drugs, and herbal products may alter drug levels. Patients should tell their oncology team about all prescription drugs, over-the-counter medicines, and supplements. This includes Ayurvedic or herbal products, because some may affect liver enzymes or increase bleeding risk, but interaction data are often limited.

People should contact their treatment team urgently for fever, chills, shortness of breath during infusion, severe diarrhoea, mouth ulcers preventing drinking, new numbness or weakness, or signs of infection. Do not self-treat fever during chemotherapy without informing the oncology team.

When to see a clinician

A clinician should review any patient on taxane chemotherapy who develops a temperature of 38°C or higher, shaking chills, worsening cough, painful urination, or new confusion, because these can signal infection during low white blood cell counts. Immediate medical review is also needed for chest tightness, wheezing, facial swelling, or rash during infusion.

Patients should also report numbness in the hands or feet, trouble buttoning clothes, difficulty walking, severe fatigue, reduced urine output, or swelling. These symptoms may lead to dose adjustment, treatment delay, supportive medicines, or a switch to another regimen.

Before starting treatment, patients should discuss fertility, pregnancy avoidance, work and travel plans, vaccination timing, and whether they have diabetes or pre-existing neuropathy. These details can affect taxane choice and monitoring.

Limitations and open questions

Taxanes are effective, but they are not the best option for every patient or every cancer subtype. Resistance can develop, and some tumours respond better to other chemotherapy drugs, targeted therapy, endocrine therapy, or immunotherapy.

Another limitation is toxicity. Peripheral neuropathy can last months or longer in some patients, and there is no perfect way to predict who will develop severe symptoms. Researchers are studying biomarkers, schedule changes, and supportive strategies to reduce nerve damage and improve selection of patients.

Evidence is strong for many standard uses, but not all taxane questions are settled. Ongoing research is examining the best sequencing with newer targeted drugs, the role of different formulations such as nab-paclitaxel, and how to personalise treatment by tumour biology and patient factors. For patients, the practical point is that taxanes are established chemotherapy drugs with proven benefit in several cancers, but the expected benefit must always be weighed against side effects and treatment goals.